Home > News > pSivida Provides Update on BrachySil(TM) Liver Program
May 25th, 2006
pSivida Provides Update on BrachySil(TM) Liver Program
Abstract:
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that the scope of the BrachySil(TM) phase IIb clinical trial for inoperable primary liver cancer has expanded to encompass a roll-out to further clinical centers in new Asian territories. In addition to the five centers currently active in Singapore, and centers in Vietnam and Malaysia, new centers are being negotiated in the Philippines and Taiwan.
Source:
businesswire
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||